Skip to content

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Pancreatic Ductal Adenocarcinoma | Colorectal Cancer | Biliary Tract Cancer

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:

* About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it
* How many people have the cancer respond (get smaller or go away) to treatment

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has one of the following cancers:

* Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer
* Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer
* Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer
* Advanced and/or unresectable BTC and has not received prior therapy for the cancer
* For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* History of severe eye disease
* For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Lieu de l'étude

Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Study Coordinator

5148908000
The Ottawa Hospital Cancer Centre ( Site 0027)
The Ottawa Hospital Cancer Centre ( Site 0027)
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Study Coordinator

613-737-7700 x70185
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Study Coordinator

5148908000
McGill University Health Centre ( Site 0023)
McGill University Health Centre ( Site 0023)
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
Merck Sharp & Dohme LLC
Participants recherchés
Plus d'informations
ID de l'étude: NCT06428409